Low expression of junctional adhesion molecule A is associated with metastasis and poor survival in pancreatic cancer

Annals of Surgical Oncology

Volumn 19, Issue 13, 2012, Pages 4330-4336

  Fong, Dominic ^a,b,c   Spizzo, Gilbert ^b,c   Mitterer, Manfred ^c   Seeber, Andreas ^b,c   Steurer, Michael ^a   Gastl, Guenther ^a   Brosch, Ines ^d   Moser, Patrizia ^d  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b TYROLEAN CANCER RESEARCH INSTITUTE   (Austria)

^c FRANZ TAPPEINER HOSPITAL   (Italy)

^d MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

JUNCTIONAL ADHESION MOLECULE A;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BILIARY STENT; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PREDICTIVE VALUE; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL TIME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; RECEPTORS, CELL SURFACE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84876463144     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2381-8     Document Type: Article

References (41)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006;244: 10-5. (Pubitemid 44297442)
3. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004;91:586-94. (Pubitemid 38624667)
4. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcita-bine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-6. (Pubitemid 46972777)
5. Martin-Padura I, Lostaglio S, Schneemann M, et al. Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J Cell Biol. 1998;142:117-27. (Pubitemid 28341144)
6. Naik UP, Eckfeld K. Junctional adhesion molecule 1 (JAM-1). J Biol Regul Homeost Agents. 2003;17:341-7. (Pubitemid 38443667)
7. Mandell KJ, Parkos CA. The JAM family of proteins. Adv Drug Deliv Rev. 2005;57:857-67. (Pubitemid 40488107)
8. Liu Y, Nusrat A, Schnell FJ, et al. Human junction adhesion molecule regulates tight junction resealing in epithelia. J Cell Sci. 2000;113(Pt 13):2363-74. (Pubitemid 30599341)
9. Liang TW, DeMarco RA, Mrsny RJ, et al. Characterization of huJAM: evidence for involvement in cell-cell contact and tight junction regulation. Am J Physiol Cell Physiol. 2000;279: C1733-43.
10. Del Maschio A, De Luigi A, Martin-Padura I, et al. Leukocyte recruitment in the cerebrospinal fluid of mice with experimental meningitis is inhibited by an antibody to junctional adhesion molecule (JAM). J Exp Med. 1999;190:1351-6. (Pubitemid 29522218)
11. Sobocka MB, Sobocki T, Banerjee P, et al. Cloning of the human platelet F11 receptor: a cell adhesion molecule member of the immunoglobulin superfamily involved in platelet aggregation. Blood. 2000;95:2600-9. (Pubitemid 30210539)
12. Naik MU, Mousa SA, Parkos CA, Naik UP. Signaling through JAM-1 and alphavbeta3 is required for the angiogenic action of bFGF: dissociation of the JAM-1 and alphavbeta3 complex. Blood. 2003;102:2108-14. (Pubitemid 37122387)
13. Kornecki E, Walkowiak B, Naik UP, Ehrlich YH. Activation of human platelets by a stimulatory monoclonal antibody. J Biol Chem. 1990;265:10042-8.
14. Aurrand-Lions M, Duncan L, Ballestrem C, Imhof BA. JAM-2, a novel immunoglobulin superfamily molecule, expressed by endothelial and lymphatic cells. J Biol Chem. 2001;276:2733-41.
15. Gupta SK, Pillarisetti K, Ohlstein EH. Platelet agonist F11 receptor is a member of the immunoglobulin superfamily and identical with junctional adhesion molecule (JAM): regulation of expression in human endothelial cells and macrophages. IUBMB Life. 2000;50:51-6.
16. Yamaguchi H, Kojima T, Ito T, et al. Transcriptional control of tight junction proteins via a protein kinase C signal pathway in human telomerase reverse transcriptase-transfected human pancreatic duct epithelial cells. Am J Pathol. 2010;177:698-712.
17. Williams LA, Martin-Padura I, Dejana E, Hogg N, Simmons DL. Identification and characterisation of human junctional adhesion molecule (JAM). Mol Immunol. 1999;36:1175-88. (Pubitemid 30078900)
18. McSherry EA, McGee SF, Jirstrom K, et al. JAM-A expression positively correlates with poor prognosis in breast cancer patients. Int J Cancer. 2009;125:1343-51.
19. Naik MU, Naik TU, Suckow AT, Duncan MK, Naik UP. Attenuation of junctional adhesion molecule-A is a contributing factor for breast cancer cell invasion. Cancer Res. 2008;68: 2194-203. (Pubitemid 351521792)
20. Gutwein P, Schramme A, Voss B, et al. Downregulation of junctional adhesion molecule-A is involved in the progression of clear cell renal cell carcinoma. Biochem Biophys Res Commun. 2009;380:387-91.
21. Chlenski A, Ketels KV, Tsao MS, et al. Tight junction protein ZO-2 is differentially expressed in normal pancreatic ducts compared to human pancreatic adenocarcinoma. Int J Cancer. 1999;82:137-44. (Pubitemid 29266119)
22. Sobin LH, Fleming ID. TNM classification of malignant tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997;80: 1803-4.
23. Martin TA, Jiang WG. Loss of tight junction barrier function and its role in cancer metastasis. Biochim Biophys Acta. 2009;1788: 872-91.
24. Shin K, Fogg VC, Margolis B. Tight junctions and cell polarity. Annu Rev Cell Dev Biol. 2006;22:207-35.
25. Lampugnani MG, Dejana E. Interendothelial junctions: structure, signalling and functional roles. Curr Opin Cell Biol. 1997;9: 674-82. (Pubitemid 27424924)
26. Mandell KJ, Babbin BA, Nusrat A, Parkos CA. Junctional adhesion molecule 1 regulates epithelial cell morphology through effects on beta1 integrins and Rap1 activity. J Biol Chem. 2005; 280:11665-74. (Pubitemid 40418481)
27. Balda MS, Matter K. Transmembrane proteins of tight junctions. Semin Cell Dev Biol. 2000;11:281-9. (Pubitemid 32066135)
28. Dejana E, Corada M, Lampugnani MG. Endothelial cell-to-cell junctions. FASEB J. 1995;9:910-8.
29. Matter K, Balda MS. Biogenesis of tight junctions: the C-terminal domain of occludin mediates basolateral targeting. J Cell Sci. 1998;111(Pt 4):511-9. (Pubitemid 28098399)
30. Tan X, Egami H, Ishikawa S, et al. Arrangement of expression and distribution of tight junction protein claudin-1 in cell dissociation of pancreatic cancer cells. Int J Oncol. 2004;25:1567-74.
31. Borka K, Kaliszky P, Szabo E, et al. Claudin expression in pancreatic endocrine tumors as compared with ductal adenocar-cinomas. Virchows Arch. 2007;450:549-57. (Pubitemid 46676254)
32. Takai E, Tan X, Tamori Y, Hirota M, Egami H, Ogawa M. Correlation of translocation of tight junction protein Zonula occludens-1 and activation of epidermal growth factor receptor in the regulation of invasion of pancreatic cancer cells. Int J Oncol. 2005;27:645-51.
33. Michl P, Barth C, Buchholz M, et al. Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. Cancer Res. 2003;63:6265-71. (Pubitemid 37255173)
34. Tsutsumi K, Sato N, Tanabe R, et al. Claudin-4 expression predicts survival in pancreatic ductal adenocarcinoma. Ann Surg Oncol. doi:10.1245/s10434-011-1970-2.
35. Laukoetter MG, Nava P, Lee WY, et al. JAM-A regulates permeability and inflammation in the intestine in vivo. J Exp Med. 2007;204:3067-76.
36. Ghislin S, Obino D, Middendorp S, Boggetto N, Alcaide-Loridan C, Deshayes F. Junctional adhesion molecules are required for melanoma cell lines transendothelial migration in vitro. Pigment Cell Melanoma Res. 2011;24:504-11.
37. Nava P, Capaldo CT, Koch S, et al. JAM-A regulates epithelial proliferation through Akt/beta-catenin signalling. EMBO Rep. 2011;12:314-20.
38. Amieva MR, Vogelmann R, Covacci A, Tompkins LS, Nelson WJ, Falkow S. Disruption of the epithelial apical-junctional complex by Helicobacter pylori CagA. Science. 2003;300: 1430-4. (Pubitemid 36638162)
39. McSherry EA, Brennan K, Hudson L, Hill AD, Hopkins AM. Breast cancer cell migration is regulated through junctional adhesion molecule-A-mediated activation of Rap1 GTPase. Breast Cancer Res. 2011;13:R31.
40. Gotte M, Mohr C, Koo CY, et al. miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene. 2010;29:6569-80.
41. Martin TA, Watkins G, Mansel RE, Jiang WG. Loss of tight junction plaque molecules in breast cancer tissues is associated with a poor prognosis in patients with breast cancer. Eur J Cancer. 2004;40:2717-25. (Pubitemid 39574723)